BG104731A - Method for the production of 5-lipooxygenase inhibitors having different heterocyclic ring systems - Google Patents

Method for the production of 5-lipooxygenase inhibitors having different heterocyclic ring systems

Info

Publication number
BG104731A
BG104731A BG104731A BG10473100A BG104731A BG 104731 A BG104731 A BG 104731A BG 104731 A BG104731 A BG 104731A BG 10473100 A BG10473100 A BG 10473100A BG 104731 A BG104731 A BG 104731A
Authority
BG
Bulgaria
Prior art keywords
formula
production
heterocyclic ring
ring systems
different heterocyclic
Prior art date
Application number
BG104731A
Other languages
Bulgarian (bg)
English (en)
Inventor
Timothy Norris
John Lambert
Megan HNATOW
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG104731A publication Critical patent/BG104731A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG104731A 1999-08-31 2000-08-29 Method for the production of 5-lipooxygenase inhibitors having different heterocyclic ring systems BG104731A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15161599P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
BG104731A true BG104731A (en) 2001-09-28

Family

ID=22539529

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104731A BG104731A (en) 1999-08-31 2000-08-29 Method for the production of 5-lipooxygenase inhibitors having different heterocyclic ring systems

Country Status (33)

Country Link
US (1) US6346624B1 (xx)
EP (1) EP1081143A1 (xx)
JP (1) JP2001106682A (xx)
KR (1) KR20010050256A (xx)
CN (1) CN1286250A (xx)
AP (1) AP2000001910A0 (xx)
AU (1) AU5360300A (xx)
BG (1) BG104731A (xx)
BR (1) BR0003945A (xx)
CA (1) CA2317097A1 (xx)
CZ (1) CZ20003158A3 (xx)
EA (1) EA200000801A1 (xx)
EE (1) EE200000512A (xx)
GT (1) GT200000142A (xx)
HR (1) HRP20000564A2 (xx)
HU (1) HUP0003439A3 (xx)
ID (1) ID27129A (xx)
IL (1) IL138087A0 (xx)
IS (1) IS5603A (xx)
MA (1) MA26751A1 (xx)
NO (1) NO20004313L (xx)
NZ (1) NZ506632A (xx)
OA (1) OA11452A (xx)
PA (1) PA8499701A1 (xx)
PE (1) PE20010520A1 (xx)
PL (1) PL342281A1 (xx)
SG (1) SG87146A1 (xx)
SK (1) SK12872000A3 (xx)
SV (1) SV2002000159A (xx)
TN (1) TNSN00177A1 (xx)
TR (1) TR200002529A2 (xx)
UY (1) UY26314A1 (xx)
ZA (1) ZA200004435B (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6669042B1 (en) * 2002-09-30 2003-12-30 Hewlett-Packard Development Company, L.P. Integrated positioning and locking device
EP1834953A1 (en) * 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063928A (en) * 1994-10-18 2000-05-16 Pfizer Inc 5-lipoxygenase inhibitors
US5883106A (en) * 1994-10-18 1999-03-16 Pfizer Inc. 5-lipoxygenase inhibitors
SK281577B6 (sk) 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze
US6239285B1 (en) * 1998-02-06 2001-05-29 Pfizer Inc Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems

Also Published As

Publication number Publication date
TR200002529A2 (tr) 2001-04-20
PE20010520A1 (es) 2001-04-28
HUP0003439A3 (en) 2002-08-28
SV2002000159A (es) 2002-01-23
IL138087A0 (en) 2001-10-31
CA2317097A1 (en) 2001-02-28
HU0003439D0 (en) 2000-08-30
SG87146A1 (en) 2002-03-19
OA11452A (en) 2003-12-08
SK12872000A3 (sk) 2001-11-06
CZ20003158A3 (cs) 2001-09-12
PA8499701A1 (es) 2001-12-14
GT200000142A (es) 2002-02-19
NO20004313L (no) 2001-03-01
MA26751A1 (fr) 2004-12-20
CN1286250A (zh) 2001-03-07
JP2001106682A (ja) 2001-04-17
US6346624B1 (en) 2002-02-12
EP1081143A1 (en) 2001-03-07
TNSN00177A1 (fr) 2005-11-10
AP2000001910A0 (en) 2000-09-30
HRP20000564A2 (en) 2001-12-31
ID27129A (id) 2001-03-01
BR0003945A (pt) 2001-04-03
HUP0003439A2 (hu) 2001-08-28
EA200000801A1 (ru) 2001-04-23
IS5603A (is) 2001-03-01
EE200000512A (et) 2001-04-16
UY26314A1 (es) 2001-04-30
KR20010050256A (ko) 2001-06-15
PL342281A1 (en) 2001-03-12
ZA200004435B (en) 2002-02-28
NO20004313D0 (no) 2000-08-30
NZ506632A (en) 2002-02-01
AU5360300A (en) 2001-03-08

Similar Documents

Publication Publication Date Title
AR023152A1 (es) Compuesto tienopirimidina, procedimiento para producirlo, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dichacomposicion
WO2004010515A3 (en) Method of synthesizing electrochemically active materials from a slurry of precursors
WO2003082205A3 (en) Compounds and methods
NZ504106A (en) Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
WO2002024632A3 (en) Substituted aminopropoxyaryl derivatives useful as agonists for lxr
ME00440B (me) Novi $g(b kristalni oblik tercijalne butilaminske soli perindoprila, postupak dobijanja i farmaceutske kompozicije koje sadrže isto
AU2001278408A1 (en) Method for the production of precise components by means of laser sintering
JPS5214789A (en) Process for preparing 3-substiuted cephem compounds by ring closure
NZ503912A (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists
SI1165049T1 (en) Agglomerates by crystallisation
AU2003223340A1 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
AU2001277629A1 (en) Compositions with vascular damaging activity
BG104731A (en) Method for the production of 5-lipooxygenase inhibitors having different heterocyclic ring systems
DE69807952D1 (de) Verfahren zur Verbesserung der Aufladbarkeit einer Pulverlacke
EP1435353A4 (en) NEW HETEROCYCLIC COMPOUND AND ANTI-INFLAMMATORY AGENT
AU6474200A (en) Process for the preparation of a pyridinemethanol compound
GR3020583T3 (en) Substituted pyridinesulfonamide compounds, herbicidal compositions containing them, and process for their production
WO2002072567A3 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
MXPA04000978A (es) Procedimiento para la produccion de 4-amino-2,5-bisheterociclilquinazolinas.
AU4250200A (en) Ppar-(gamma) agonists as agents for the treatment of type ii diabetes
AU3814800A (en) Enantiomers of mercapto lactones and processes for their synthesis
JPS52156805A (en) Novel perfluorononenyl ethers and their preparation
SG149005A1 (en) Process for the preparation of thiazolopyrimidines
WO1992018474A3 (en) Novel 2-spirocyclopropyl cephalosporin sulfone derivatives and processes for the preparation thereof
MY103631A (en) Certain insecticidal 6-(phenoxy-2-pyridyl)-methyl-neo-phental ethers